Skip to main content

Fungal Infection clinical trials at UC Health
3 in progress, 2 open to eligible people

  • A Study of Experimental Rezafungin Compared to Caspofungin For Candidemia and/or Invasive Candidiasis (yeast infection in blood)

    open to eligible people ages 18 years and up

    The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by optional oral fluconazole).

    at UC Davis

  • Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole

    open to eligible people ages 19 years and up

    This is a prospective, multi-center, randomized, open-label parallel arm study involving patients with proven or probable invasive endemic fungal infection to ascertain the pharmacokinetics, safety, efficacy, tolerability and health economics of oral SUBA-itraconazole compared to conventional itraconazole. Patients will receive randomized open-label study drug (SUBA-itraconazole or conventional itraconazole) over a 42 day period and then continue therapy until Day 180. Patients will be stratified based on clinically reported infection with the human immunodeficiency virus (HIV).

    at UC Davis

  • Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant

    Sorry, in progress, not accepting new patients

    This randomized phase III trial studies how well caspofungin acetate works compared to fluconazole or voriconazole in preventing fungal infections in patients following donor stem cell transplant. Caspofungin acetate, fluconazole, and voriconazole may be effective in preventing fungal infections in patients following donor stem cell transplant. It is not yet known whether caspofungin acetate is more effective than fluconazole or voriconazole in preventing fungal infections in patients following donor stem cell transplant.

    at UCSF

Last updated: